Human Complement Component 9, C9 ELISA Kit

Human Complement Component 9, C9 ELISA Kit

產品詳情

產品評價

靶點詳情

產品詳情

產品評價

相關產品

靶點詳情

Most popular with customers

產品中心

信號通路

技術信息

聯系信息

說明書下載

中文名稱：

人補體蛋白9(C9)酶聯免疫試劑盒
貨號：

CSB-E14011h
規格：

96T/48T
價格：

￥3600/￥2500
促銷：
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品描述：

人補體蛋白9(C9)酶聯免疫試劑盒（CSB-E14011h）為雙抗夾心法ELISA試劑盒，定量檢測血清、血漿、尿液樣本中的C9含量。人補體蛋白9(C9)是補體系統中的重要成分，參與膜攻擊復合物（MAC）的形成，對病原體和異常細胞具有溶解作用。其研究背景涉及衰老、神經退行性疾病等，機制上與補體激活、炎癥反應和細胞凋亡密切相關。試劑盒檢測范圍為10.97 pg/mL-8000 pg/mL，適用于科研領域中對補體系統功能的基礎研究，如炎癥反應機制解析、自身免疫性疾病模型中的補體激活評估，或通過體液樣本探索C9在感染、腎臟疾病等病理條件下的生物標志物價值本品僅用于科研，不用于臨床診斷，產品具體參數及操作步驟詳見產品說明書。
別名：

C9; Complement component C9
縮寫：

C9
Uniprot No.：

P02748
種屬：

Homo sapiens (Human)
樣本類型：

serum, plasma, urine
檢測范圍：

10.97 pg/mL-8000 pg/mL
靈敏度：

10.97 pg/mL
反應時間：

1-5h
樣本體積：

50-100ul
檢測波長：

450 nm
研究領域：

Immunology
測定原理：

quantitative
測定方法：

Sandwich

精密度：

線性度：

To assess the linearity of the assay, samples were spiked with high concentrations of human C9 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
	Sample	Serum(n=4)
1:2000	Average %	96
	Range %	90-104
1:4000	Average %	91
	Range %	87-98
1:8000	Average %	95
	Range %	90-110
1:16000	Average %	96
	Range %	89-100

回收率：

The recovery of human C9 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

Sample Type	Average % Recovery	Range
Serum (n=5)	96	92-101
EDTA plasma (n=4)	97	87-106

標準曲線：

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

pg/ml	OD1	OD2	Average	Corrected
8000	2.577	2.514	2.546	2.455
2666.7	1.845	1.864	1.855	1.764
888.9	1.239	1.213	1.226	1.135
296.3	0.851	0.844	0.848	0.757
98.8	0.388	0.399	0.394	0.303
32.9	0.214	0.207	0.211	0.120
10.97	0.139	0.142	0.141	0.050
0	0.089	0.093	0.091

數據處理：

ELISA操作視頻及標曲繪制軟件下載
貨期：

3-5 working days

功能：

Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C9 is the pore-forming subunit of the MAC.
基因功能參考文獻：
1. The data supports the assumption that C9 gene expression may stimulate the expression of inflammatory (NLRP3) and angiogenic growth factors (VEGF) in retinal pigment epithelial cells. PMID: 30090015
2. Serum-expressed apolipoprotein B-100 protein, C9 Complement, and gelsolin can be used for differential diagnosis of Barrertts esophagus and adenocarcinoma of esophagus. PMID: 26404905
3. Data indicate that complement C9 binds to the ATPase domain of mortalin. PMID: 24719326
4. Liver biopsy specimens from chronically hepatitis C virus-infected patients exhibited a lower level of C9 mRNA expression than liver biopsy specimens from unrelated disease or healthy control human liver RNA. PMID: 23487461
5. the haploinsufficiency of C9, a terminal complement complex component, engenders reduced intraocular secretion of VEGF and decreased risk for CNV development. PMID: 22190594
6. C9 and fucosylated form could serve as a useful marker for SQLC. PMID: 21840429
7. It was concluded that variations in the complement component 9 gene are unlikely to influence clearance of chronic hepatitis B virus infection and hepatocellular carcinoma occurrence. PMID: 21380615
8. Mapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9. PMID: 21507937
9. These results suggested that the lack of membrane attack complex because of an Arg95Stop mutation of the complement component 9 gene predisposed patients to pathognomonic glomerulonephritis. PMID: 21057849
10. provided evidence for the recognition of membrane-bound C9 on complement-lysed ghosts by an antibody specific for the helix-turn-helix fold. PMID: 20153530
11. Data show that mortalin supports cancer cell resistance to complement-dependent cytotoxicity and suggest consideration of mortalin as a novel target for cancer adjuvant immunotherapy. PMID: 19739077
12. The human complement C9 gene: structural analysis of the 5' gene region and genetic polymorphism studies. PMID: 11881818
13. C9 binding is dependent on the N-terminal modules (thrombospondin type 1 and low-density lipoprotein receptor class A) of C8 alpha together with the C8 alpha membrane attack complex/perforin domain. PMID: 12463754
14. Founder effect was demonstrated for the R95X mutation of the C9 gene in Japanese PMID: 12596049
15. results indicate that the principal binding site for C9 lies within the MACPF domain of C8alpha PMID: 16618117
16. analysis of the CD59-C9 binding interaction PMID: 16844690
顯示更多

收起更多
相關疾?。?/div>
Complement component 9 deficiency (C9D); Macular degeneration, age-related, 15 (ARMD15)
亞細胞定位：

Secreted. Target cell membrane; Multi-pass membrane protein.
蛋白家族：

Complement C6/C7/C8/C9 family
組織特異性：

Plasma (at protein level).
數據庫鏈接：

HGNC: 1358

OMIM: 120940

KEGG: hsa:735

STRING: 9606.ENSP00000263408

UniGene: Hs.654443

Intra-assay Precision (Precision within an assay): CV%<8%

Three samples of known concentration were tested twenty times on one plate to assess.

Inter-assay Precision (Precision between assays): CV%<10%

Three samples of known concentration were tested in twenty assays to assess.